GC Mediai (CEO Kim Jin-tae, formerly Ubcare) is accelerating its transition into a “medical OS (operating system)” company that leads an artificial intelligence (AI)-based healthcare ecosystem beyond EMR (electronic medical records).

At a recent corporate briefing, the company unveiled the commercialization roadmap for “Uisarang AI,” an AI-based clinical and operations automation solution, and its strategy to build the next-generation open platform “Uisarang AI 2.0.”

The company aims to make 2026 the first year of “large-scale AI commercialization” and to secure mid- to long-term growth drivers as a platform that connects the entire healthcare ecosystem.

Preempting the ‘medical AI’ market with dominant infrastructure and technology

GC Mediai cited technological capabilities, infrastructure, and capital strength as the key conditions for successful adoption of medical AI, presenting its own distinctive competitive edge. The company currently has a dedicated AI organization and an in-house large language model (LLM) based on H100.

Its strengths include infrastructure such as a network of more than 16,000 hospitals and clinics nationwide, over 8,000 pharmacies, and the patient platform “Ddokdak,” which has more than 12 million users. Through this, it secures over 200 million cases of high-quality medical data annually, and its share of the medical data supply market also reaches 80%. The company plans to preempt the medical AI market by combining this technological capability with its vast data resources.

‘Uisarang AI’ to be commercialized in July… Transforming the clinical work environment

The company will officially commercialize Uisarang AI in July. Once Uisarang AI is introduced, healthcare professionals will be able to leverage the latest medical knowledge in real time to support diagnosis and prescriptions.

In addition, by automatically generating clinical records and minimizing repetitive data entry, the solution will improve efficiency in consultations and charting tasks, while features such as automatic creation of claims files and early alerts on potential drug price reductions will help reduce administrative workload.

This is expected to enable medical staff to focus more on their core duties, such as patient consultations and treatment.

Next-generation medical OS vision… Transition to a data- and platform-centric structure

GC Mediai’s mid- to long-term vision is to build “Uisarang AI 2.0,” a next-generation open platform at the center of all healthcare service connections.

Moving away from the existing closed, software-centric structure, the company plans to expand its business model across the entire healthcare ecosystem by completing an extensible medical OS that integrates various external solutions, including remote consultation apps and health monitoring devices.

In the first phase, the company will focus beyond subscription-based solution revenues on data-driven marketing and platform entry fees, ultimately targeting the domestic digital healthcare market. It aims to present a high value-added business model that competes on value rather than price through enhanced customer experience and tailored insights.

CEO Kim Jin-tae said, “2026 is the year in which GC Mediai’s AI transition direction has been concretely presented,” adding, “Based on the commercialization of Uisarang AI, the company will leap forward as a medical OS provider leading an AI-based healthcare ecosystem.”

Popular News